Expressions of Interest (EOIs) are now open for funding of up to $1 million for up to 24 months, to develop innovative preventative, diagnostic, therapeutic and/or disease management devices focused on cardiovascular disease and/or complications of diabetes (type 1 or 2).
This investment is being made available through the Targeted Translation Research Accelerator (TTRA) for Drugs and Devices, an initiative of the Medical Research Future Fund, delivered by MTPConnect. This opportunity is for Stream 2: Devices only.
The TTRA investment aims to nurture these devices to reach commercial proof-of-concept with the potential to attract further capital and support.
Activities supported by the investment will include, but are not limited to, prototype refinement and product testing, clinical trial activity and regulatory support.
Ideas and concepts with no technical validation at the time of application are out of scope for TTRA investment. Please see the eligibility criteria for the required minimum stage of development for device applications. Validation must include data from your own work and/or a partner’s work and can also include data from published literature or a patent.
This program requires a co-contribution to be eligible. A cash co-contribution relative to the value of the TTRA funding request must be provided by the applicant and/or applicant partner(s). Additional in-kind or cash contributions above this threshold will be viewed favourably.
BEFORE YOU BEGIN
This funding is available through a competitive process.
TTRA can provide up to a maximum of $1 million over 24 months.
Applicants are encouraged to read the TTRA Funding Guidelines carefully before commencing an application.
To be eligible for consideration, applications must satisfy all the requirements set out in the Funding Guidelines. An application may be considered ineligible and excluded from further consideration if it contravenes an eligibility rule or other requirement as set out in the Funding Guidelines.
Application to this opportunity is a multi-step process:
Phase 0 Notice of Intent (NOI): All companies intending to submit an expression of interest must first submit a brief NOI, including the project title and a public summary of the proposed project. Once a NOI is submitted, applicants will automatically receive a link to the expression of interest form via email.
Phase I Expression of Interest (EOI): All eligible applications are to be submitted as a non-confidential EOI. EOIs need to clearly articulate the challenge and solution, outline completed and/or planned technical and commercial activities (substantiated with non-confidential data) and describe the strengths of the team. EOIs will be evaluated by the TTRA Selection Panel using selection criteria published in the Funding Guidelines.
The most meritorious EOIs, as determined by the TTRA Selection Panel, will be invited to progress to Phase II. The merits of an application are based on how well it meets the selection criteria and how it compares to other eligible applications.
Phase II Due Diligence Consultation: Applicants who reach Phase II will take part in Due Diligence Consultation which will be held via videoconference.
Confidential Disclosure Agreements will be entered into with applicants whose applications move beyond the EOI stage to allow for a complete review and assessment of your product/solution.
Due Diligence Consultations will provide an opportunity for applicants to address TTRA Selection Panel feedback on their EOI, have a two-way due diligence conversation with TTRA Selection Panel representatives on the technical aspects of the project and its commercial potential, and allow for financial vetting with respect to co-contributions. Time will be provided for the applicant to ask general questions on commercialisation as well.
The outcome of the consultation and due diligence evaluation will be assessed by the TTRA Selection Panel. The most meritorious applications, as determined by the TTRA Selection Panel post Phase II, will be invited to progress to Phase III and submit a Full Proposal.
Phase III Full Proposal: Full Proposal applications will expand on the EOI application to provide a more comprehensive outline of the project.
Full Proposal applications will be reviewed by the TTRA Investment Panel, an independent, national and international panel of clinical, research, lived experience and commercial experts, against the selection criteria articulated in the Funding Guidelines. The TTRA Investment Panel will make recommendations for funding award to the most meritorious Full Proposals.
Funding Award: Applicants whose proposals are awarded funding will enter into a funding agreement with MTPConnect to receive the awarded investment over the defined project term to be paid in accordance with the agreed budget and a quarterly payment schedule. Payments are paid in advance and are subject to satisfactory progress on the project plan and achieving agreed milestones.
The funding agreement will have a clear project plan which will include resourcing, timelines, milestones, go/no-go decision points and a risk register. Investment recipients will have regular reporting and audited financial obligations to MTPConnect.
At all stages of the application process, unsuccessful applicants will be provided with feedback on their bid.
EOI PROPOSAL CLOSING DATE
Applicants must first submit this NOI form to gain access to the EOI form.
EOI submission closes on Monday 30 March 2026 at 16:00 AEDT (Australian Eastern Daylight Time). Late applications will not be accepted.
COMPLETING THIS NOI FORM
Please note that the nominated project lead and user who created the application form will receive all correspondence throughout the application process. Please check your Junk/Spam mailbox to confirm that correspondence has not been incorrectly filtered out of your inbox.
Please do not use abbreviations unless fully explained.
Questions marked with an asterisk (*) are required. Please do not leave any answers blank. State for instance "not applicable" or "unknown at this stage”.
Tips are provided throughout to guide you on the type of information or level of detail to include.
For assistance in completing the EOI form, please contact:
For any technical enquiries, please contact the SmartyGrants Help Hub:
Fill
Out